SLC9C1 and diabetic cardiomyopathy: The observation that SGLT2i reduce cytosolic Na+ and Ca2+ levels and inhibit the sodium-hydrogen exchanger (NHE) in mouse cardiomyocytes, which are known to be increased in diabetic cardiomyopathy and HF (Baartscheer et al., 2017; Uthman et al., 2018), suggests that the cardioprotective effect of SGLT2i might be due to the direct inhibition of cardiac NHE flux and the reduction of cytosolic Na+ and Ca2+ levels.